$SLN entered into a definitive buyout agreement with Merck KGaA valued at roughly $1.3 billion in equity and $1.1 billion in enterprise value. Under the terms, Merck KGaA will acquire the business for $20.00 per ADS in cash, marking a 130% premium over its October 16 close following encouraging Phase 2 divesiran results in polycythemia vera.
$SLN $EYPT $IRON $MANE $ATNM $EVAX $NAUT $SXTC $MTNB $CDT
For more biotech updates, join us on 🔗 BioPharmCatalyst 📰 Articles section
ESMO Abstracts drop today. Let us know what you think makes an oncology abstract worth reading? ↓↓
25%Novel mechanism
0%Large sample size
0%Clear endpoint
75%Strong biomarker
4 votes • 2 hours
Press Release 👇
biopharmcatalyst.com/company…
For more check our M&A tracker:
biopharmcatalyst.com/analysi…
$EYPT reported a second Phase 3 DURAVYU failure in wet AMD versus Eylea. The company is ending wet AMD development and cutting its workforce by 53% for
$MDXH reported preliminary Q3 2026 revenue of $22.7 million—flat year-over-year and missing consensus—and pulled its full-year guidance of $110M–$115M after sales force attrition drove an 11% drop in tissue test volume. Holding $31.7 million in cash, the company must stabilize key sales territories to regain Q2 growth momentum.
$ADIL $MDXH $MBRX $CRIS $REVB $IBO $ACTU $TCRT $REVB $JAGX
For more biotech updates, join us on 🔗 BioPharmCatalyst 📰 Articles section
$IRD announced FDA approval for sNDA for phentolamine ophthalmic solution 0.75% for the treatment of presbyopia in adults
